{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:02:33Z","timestamp":1793826153476,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.04.064","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T15:50:16Z","timestamp":1684425016000},"page":"3898-3906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0471-206X","authenticated-orcid":false,"given":"Christine A.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"August","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1652-3263","authenticated-orcid":false,"given":"Stephan","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peta-Gay Jackson","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Knightly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Brasel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongHong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Panther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2023.04.064_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1586\/erv.12.84","article-title":"Chikungunya virus and prospects for a vaccine","volume":"11","author":"Weaver","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.064_b0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jbspin.2018.03.019","article-title":"Incidence of articular pain and arthritis after chikungunya fever in the Americas: a systematic review of the literature and meta-analysis","volume":"85","author":"Edington","year":"2018","journal-title":"Joint Bone Spine"},{"issue":"E060202","key":"10.1016\/j.vaccine.2023.04.064_b0015","first-page":"3","article-title":"Chikungunya outbreak in Reunion: epidemiology and surveillance, 2005 to early January 2006","volume":"11","author":"Paquet","year":"2006","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.04.064_b0020","doi-asserted-by":"crossref","first-page":"e00104","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control chikungunya virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.064_b0025","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/acr.22900","article-title":"Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis","volume":"68","author":"Rodr\u00edguez-Morales","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vaccine.2023.04.064_b0030","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4269\/ajtmh.17-0957","article-title":"Perinatal outcomes in vertically infected neonates during a chikungunya outbreak on the island of Curacao","volume":"99","author":"van Enter","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.04.064_b0035","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12879-021-05876-4","article-title":"Neurologic sequelae of severe chikungunya infection in the first 6 months of life: a prospective cohort study 24-months post-infection","volume":"21","author":"van Ewijk","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.04.064_b0040","unstructured":"World Health Organization Chikungunya 2020. Page last reviewed 15 September. Accessed July 9, 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chikungunya."},{"key":"10.1016\/j.vaccine.2023.04.064_b0045","unstructured":"Centers for Disease Control and Prevention Chikungunya virus 2020. Page last reviewed November 6. Accessed April 22, 2021. https:\/\/www.cdc.gov\/chikungunya\/index.html."},{"key":"10.1016\/j.vaccine.2023.04.064_b0050","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3389\/fmicb.2019.02881","article-title":"Recent progress in vaccine development against chikungunya virus","volume":"10","author":"Gao","year":"2019","journal-title":"Front Microbiol"},{"issue":"7715","key":"10.1016\/j.vaccine.2023.04.064_b0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-018-0318-5","article-title":"Challenges and opportunities in controlling mosquito-borne infections","volume":"559","author":"Ferguson","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.064_b0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1086\/600381","article-title":"Prophylaxis and therapy for Chikungunya virus infection","volume":"200","author":"Couderc","year":"2009","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.064_b0065","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.064_b0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/infdis\/jis033","article-title":"Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection","volume":"205","author":"Kam","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.064_b0075","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3201\/eid1305.070015","article-title":"Chikungunya virus in US travelers returning from India","volume":"13","author":"Lanciotti","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2023.04.064_b0080","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.04.064_b0085","unstructured":"ClinicalTrials.gov Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects (NCT03325075) 2020. Page last reviewed January 21. Accessed April 22, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03325075."},{"issue":"10165","key":"10.1016\/j.vaccine.2023.04.064_b0090","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.064_b0095","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.064_b0100","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.04.064_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.064_b0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41577-019-0243-3","article-title":"Novel vaccine technologies for the 21st century","volume":"20","author":"Mascola","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.04.064_b0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.064_b0120","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum Vaccin Immunother"},{"issue":"25","key":"10.1016\/j.vaccine.2023.04.064_b0125","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2023.04.064_b0130","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2023.04.064_b0135","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.064_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.04.064_b0145","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.064_b0150","unstructured":"European Medicines Agency EMA Recommends First COVID-19 Vaccine for Authorization in the EU 2020. Page last reviewed December 21. Accessed July 9, 2021. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-first-covid-19-vaccine-authorisation-eu."},{"key":"10.1016\/j.vaccine.2023.04.064_b0155","unstructured":"European Medicines Agency EMA Recommends COVID-19 Vaccine Moderna for Authorization in the EU 2021. Page last reviewed January 6. Accessed July 9, 2021. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-covid-19-vaccine-moderna-authorisation-eu."},{"key":"10.1016\/j.vaccine.2023.04.064_b0160","unstructured":"United States Food and Drug Administration Moderna COVID-19 Vaccine 2020. Page last reviewed December 18. Accessed July 9, 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccine."},{"key":"10.1016\/j.vaccine.2023.04.064_b0165","unstructured":"United States Food and Drug Administration Pfizer-BioNTech COVID-19 Vaccine 2020. Page last reviewed December 11. Accessed July 9, 2021. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/pfizer-biontech-covid-19-vaccine."},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.064_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003764","article-title":"High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines","volume":"9","author":"Yoon","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.064_b0175","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","article-title":"A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus","volume":"27","author":"August","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.064_b0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/vbz.2014.1680","article-title":"Updates on chikungunya epidemiology, clinical disease, and diagnostics","volume":"15","author":"Sam","year":"2015","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.064_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010069","article-title":"The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines","volume":"16","author":"Bettis","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.04.064_b0190","first-page":"471","article-title":"Re-emergence of Chikungunya and O'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships","volume":"81","author":"Powers","year":"2000","journal-title":"J Gen Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2023.04.064_b0195","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:10Z","timestamp":1759404370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23004887"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}